This inventor holds 1 USPTO granted patent. Top assignee: Allogene Therapeutics, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Michael C Yi: Innovator in T Cell Recognition Mitigation
Introduction
Michael C Yi is a prominent inventor based in San Mateo, California. He has made significant contributions to the field of immunology, particularly in the area of T cell recognition. His innovative work has led to the development of a patent that addresses critical challenges in cell therapy.
Latest Patents
Michael C Yi holds a patent titled "Knockdown or Knockout of One or More of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to Mitigate T Cell Recognition of Allogeneic Cell Products." This patent represents a significant advancement in the ability to enhance the efficacy of allogeneic cell therapies by reducing T cell recognition.
Career Highlights
Currently, Michael C Yi is associated with Allogene Therapeutics, Inc., a company focused on developing innovative cell therapies. His work at Allogene Therapeutics has positioned him as a key player in the advancement of therapeutic solutions for patients.
Collaborations
Michael has collaborated with notable colleagues, including Thomas John Van Blarcom and Michael Thomas Bethune. These collaborations have further enriched his research and development efforts in the field.
Conclusion
Michael C Yi's contributions to immunology and cell therapy are noteworthy, and his patent reflects his commitment to advancing medical science. His work continues to pave the way for innovative solutions in the treatment of various diseases.